Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma

Background Programmed cell death receptor-1 (PD-1)-blocking antibodies are approved to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) cases ineligible for curative surgery or radiation. Notwithstanding, some patients experience inadequate responses or severe immune-rel...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jayesh Desai, Stephane Dalle, Jermaine Coward, Daniel Brungs, Andrew Mant, Margaret McGrath, Andrea Tazbirkova, Piotr Koralewski, Iwona Lugowska, Arunee Dechaphunkul, Virote Sriuranpong, James Oliviero, Philip Clingan, Rahul Ladwa, Eva Muñoz-Couselo, Henri Montaudié, Miguel-Ángel Berciano-Guerrero, Dean Laurence Harris, Susan Arnold, Samuel Fourie, Andriy Kurochkin, Daniel R Malan, Vinay Sharma, Hong Shue, Chaiyut Charoentum, Oleksandr Dudnichenko
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2023-10-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/11/10/e007637.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!